Quick Takeaways
- Capital International Investors filed SCHEDULE 13G for Ascendis Pharma AS Common Stock (ASND).
- Disclosed ownership: 5.6%.
- Date of event: 30 Jun 2025.
Capital International Investors - 30 Jun 2025 SCHEDULE 13G Report for Ascendis Pharma AS Common Stock (ASND)
- Filing Manager
- Capital International Investors
- Reporting Manager
- Capital International Investors
- Security
- Ascendis Pharma AS Common Stock
- Symbol
- ASND
- Shares outstanding
- 55,521,875 shares
- Disclosed Ownership
- 3,109,225 shares
- Ownership
- 5.6%
- Form type
- SCHEDULE 13G
- Filing time
- 13 Aug 2025, 12:49:42 UTC
- Date of event
- 30 Jun 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Capital International Investors disclosed 5.6% ownership in Ascendis Pharma AS Common Stock (ASND) on 30 Jun 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 13 Aug 2025, 12:49.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Capital International Investors | 5.6% | 3,109,225 | 3,099,512 | 0 | Jae Won Chung | Vice President and Senior Counsel II, Capital Research and Management Company |